Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Increased by Captrust Financial Advisors

Captrust Financial Advisors raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 13.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,074 shares of the biotechnology company’s stock after acquiring an additional 2,035 shares during the period. Captrust Financial Advisors’ holdings in Arrowhead Pharmaceuticals were worth $321,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $38,000. Van ECK Associates Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares during the last quarter. KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $190,000. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $205,000. Institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday. StockNews.com raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 14th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Citigroup reduced their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research report on Tuesday, May 13th. Finally, B. Riley reaffirmed a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $42.13.

Arrowhead Pharmaceuticals Trading Up 3.5%

Shares of ARWR opened at $16.29 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -3.15 and a beta of 0.89. The stock’s 50-day moving average price is $13.33 and its 200 day moving average price is $17.75. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the prior year, the company posted ($1.02) earnings per share. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. The trade was a 3.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 275,880 shares of company stock worth $4,034,037. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.